Skip to main content
SpringerLink
Log in

Growth Hormone Deficiency in Adults

The Role of Replacement Therapy

  • Leading Article
  • Published:
BioDrugs Aims and scope Submit manuscript

Summary

Although growth hormone has been in clinical use for almost 40 years to promote linear growth in children with growth hormone deficiency, replacement therapy in adults was previously not deemed clinically indicated. However, intensive research over the past decade has led to important advances in our medical knowledge and improvements in the care for patients with growth hormone deficiency. Well-controlled clinical trials have demonstrated beneficial effects of replacement therapy with recombinant human prion-free growth hormone (rhGH; somatropin). The most important restoration parameters include reduction of cardiovascular risk factors and improved lipid profile, normalised body composition, improved exercise capacity and bone mass, as well as enhanced psychological well-being.

Some important issues regarding growth hormone deficiency and long term somatropin treatment are unresolved, such as diagnostic criteria and the potential for malignancy and impaired glucose tolerance. Furthermore, the effect on hard end-points such as life expectancy or vertebral fracture rate is unknown, but is expected to emerge from physician-managed, multinational databases. Consequently, at this point somatropin therapy should be given in conjunction with clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Raben MS. Clinical use of human growth hormone. N Engl J Med 1962; 266: 82–6

    Article  PubMed  CAS  Google Scholar 

  2. Falkheden T. Pathophysiology-studies following hypophysectomy in man [thesis]. Goteborg; University of Goteborg, 1963

  3. Cuneo RC, Salomon F, McGauley GA, et al. The growth hormone deficiency syndrome in adults. Clin Endocrinol 1992; 37: 387–97

    Article  CAS  Google Scholar 

  4. Rosén T, Bengtsson BÅ. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990; 336: 285–92

    Article  PubMed  Google Scholar 

  5. Bengtsson BÅ. The consequences of growth hormone deficiency in adults. Acta Endocrinol 1993; 128Suppl. 2: 1–5

    Google Scholar 

  6. Bengtsson BA. Growth hormone deficiency in adults: a new indication for recombinant human growth hormone. J Intern Med 1996; 239: 283–6

    Article  PubMed  CAS  Google Scholar 

  7. Hoffman DM, O’Sullivan AJ, Baxter RC, et al. Diagnosis of growth-hormone deficiency in adults. Lancet 1994; 343: 1064–8

    Article  PubMed  CAS  Google Scholar 

  8. Ho KK, Hoffman DM. Defining growth hormone deficiency in adults. Metabolism 1995; 44Suppl. 4: 91–6

    Article  PubMed  CAS  Google Scholar 

  9. Korbonits M, Besser M. Diagnosis of growth hormone deficiency in adults. Horm Res 1996; 46: 174–82

    Article  PubMed  CAS  Google Scholar 

  10. Nicolson A, Toogood AA, Rahim A, et al. The prevalence of severe growth hormone deficiency in adults who received growth hormone replacement in childhood. Clin Endocrinol 1996; 44: 311–6

    Article  CAS  Google Scholar 

  11. Meling TR, Nylen ES. Growth hormone deficiency in adults: a review. Am J Med sci 1996; 311(4): 153–66

    Article  PubMed  CAS  Google Scholar 

  12. Thorner MO, Bengtsson BÅ, Ho KKY, et al. The diagnosis of growth hormone deficiency (GHD) in adults (1). J Clin Endocrinol Metab 1995; 80: 3097–8

    Article  PubMed  CAS  Google Scholar 

  13. Rosén T, Edén S, Larson G, et al. Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinol 1993; 129: 195–200

    PubMed  Google Scholar 

  14. Bulow B, Hagmar L, Mikoczy Z, et al. Increased cerebrovascular mortality on patients with hypopituitarism. Clin Endocrinol 1997; 46: 75–81

    Article  CAS  Google Scholar 

  15. Thuesen L, Christiansen JS, Sørensen KE, et al. Increased myocardial contractility following growth hormone administration in normal men. Dan Med Bull 1988; 35: 193–6

    PubMed  CAS  Google Scholar 

  16. Shahi M, Beshyah SA, Hackett D, et al. Myocardial dysfunction in treated adult hypopituitarism: a possible explanation for increased cardiovascular mortality. Br Heart J 1992; 67: 92–6

    Article  PubMed  CAS  Google Scholar 

  17. Amato G, Carella C, Fazio S, et al. Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. J Clin Endocrinol Metab 1993; 77: 1671–6

    Article  PubMed  CAS  Google Scholar 

  18. Jørgensen JOL, Pedersen SA, Thuesen L, et al. Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet 1989; I: 1221–5

    Article  Google Scholar 

  19. Sacca L, Cittadini A, Fazio S. Growth hormone and the heart. Endocr Rev 1994; 15: 555–73

    PubMed  CAS  Google Scholar 

  20. Markussis V, Beshyah SA, Fisher C, et al. Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults. Lancet 1992; 340: 1188–92

    Article  PubMed  CAS  Google Scholar 

  21. Lehmann ED, Hopkins KD, Fischer C, et al. Aortic distensibility in growth hormone deficient adults. Lancet 1993; 341: 309

    Article  PubMed  CAS  Google Scholar 

  22. Johansson JO, Landin K, Tengborn L, et al. High fibrinogen and plasminogen activator inhibitor activity in growth hormonedeficient adults. Arterioscler Thromb 1994; 14: 434–7

    Article  PubMed  CAS  Google Scholar 

  23. Wüster C, Slenczka E, Ziegler R. Erhöhte prävalenz von Osteoporose und Arteriosklerose bei konventionell substituierter Hypophysenvorderlappeninsuffizienz: Bedarf einer zusätzichen Wachstumshormon substitution. Klin Wochenschr 1991; 69: 769–73

    Article  PubMed  Google Scholar 

  24. Merimee TJ, Hollander W, Fineberg SE. Studies of hyperlipidemia in the hGH-deficient state. Metabolism 1972; 21: 1053–61

    Article  PubMed  CAS  Google Scholar 

  25. Cuneo RC, Salomon F, Watts GF, et al. Growth hormone treatment improves lipids and lipoproteins in adults with growth hormone deficiency. Metabolism 1993; 42: 1519–23

    Article  PubMed  CAS  Google Scholar 

  26. de Boer H, Blok GJ, Voerman HJ, et al. Serum lipid levels in growth hormone-deficient men. Metabolism 1994; 43: 199–203

    Article  PubMed  Google Scholar 

  27. Christiansen JS, Jørgensen JOL, Pedersen SA, et al. Effects of growth hormone on body composition in adults. Horm Res 1990; 33Suppl. 4: 61–4

    Article  PubMed  Google Scholar 

  28. Rosén T, Bosaeus I, Tolli J, et al. Increased body fat mass and decreased extracellular fluid volume in adults with growth hormone deficiency. Clin Endocrinol 1993; 38: 63–71

    Article  Google Scholar 

  29. Larsson B, Svärdsudd K, Welin L, et al. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13-year follow up of participants in the study of men born in 1913. BMJ 1984; 288: 1401–4

    Article  PubMed  CAS  Google Scholar 

  30. Cuneo RC, Salomon F, Wiles CM, et al. Growth hormone treatment in growth hormone-deficient adults. II. Effects on exercise performance. J Appl Physiol 1991; 70: 695–700

    PubMed  CAS  Google Scholar 

  31. Tanner JM, Hughes PCR, Whitehouse RH. Comparative rapidity of response of height, limb muscle and limb fat to treatment with human growth hormone in patients with and without growth hormone deficiency. Acta Endocrinol 1977; 84: 681–96

    PubMed  CAS  Google Scholar 

  32. Cuneo RC, Salomon F, Wiles CM, et al. Growth hormone treatment in growth hormone-deficient adults. I. Effects on muscle mass and strength. J Appl Physiol 1991; 70: 688–94

    PubMed  CAS  Google Scholar 

  33. Cuneo RC, Salomon F, Wiles CM, et al. Skeletal muscle performance in adults with growth hormone deficiency. Horm Res 1990; 33Suppl. 4: 55–60

    Article  PubMed  Google Scholar 

  34. Holmes SJ, Economou G, Whitehouse RW, et al. Reduced bone mineral density in patients with adult onset growth hormone deficiency. J Clin Endocrinol Metab 1994; 78: 669–74

    Article  PubMed  CAS  Google Scholar 

  35. Rosén T, Hansson T, Granhed H, et al. Reduced bone mineral content in adult patients with growth hormone deficiency. Acta Endocrinol 1993; 129: 201–6

    PubMed  Google Scholar 

  36. Dean HJ, McTaggart TL, Fish DG, et al. The educational, vocational, and marital status of growth hormone-deficient adults treated with growth hormone during childhood. Am J Child Dis 1985; 139: 1105–10

    CAS  Google Scholar 

  37. Björk S, Jönsson B, Westphal O, et al. Quality of life of adults with growth hormone deficiency: a controlled study. Acta Paediatr Scand Suppl. 1989; 356: 55–9

    Article  PubMed  Google Scholar 

  38. Hunt SM, McKenna SP, Doward LC. Preliminary report on the development of a disease-specific instrument for assessing quality of life of adults with growth hormone deficiency. Acta Endocrinol 1993; 128: 37–40

    PubMed  Google Scholar 

  39. Rosén T, Wirén L, Wilhelmsen L, et al. Decreased psychological well-being in adult patients with growth hormone deficiency. Clin Endocrinol 1994; 40: 111–6

    Article  Google Scholar 

  40. Stabler B, Clopper RR, Siegel PT, et al. Links between growth hormone deficiency, adaptation and social phobia. Horm Res 1996; 45: 30–3

    Article  PubMed  CAS  Google Scholar 

  41. Henneman PH, Forbes AP, Moldawer M, et al. Effects of human growth hormone in man. J Clin Invest 1960; 39: 1223–38

    Article  PubMed  CAS  Google Scholar 

  42. Christiansen JS, Gammelgaard J, Ørskov HH, et al. Kidney function and size in normal subjects before and during growth hormone administration for one week. Eur J Clin Invest 1981; 11: 487–90

    Article  PubMed  CAS  Google Scholar 

  43. Caidahl K, Eden S, Bengtsson BÅ. Cardiovascular and renal effects of growth hormone. Clin Endocrinol 1994; 40: 393–400

    Article  CAS  Google Scholar 

  44. Fort S, Weaver JU, Monson JP, et al. The effects of flow-dose recombinant human growth hormone on cardiovascular structure and function in hypopituitary growth hormone deficient adults. Endocrinol Metab 1995; 2: 119–26

    CAS  Google Scholar 

  45. Thuesen L, Jørgensen JOL, Müller JR, et al. Short and long-term cardiovascular effects of growth hormone therapy in growth hormone deficient adults. Clin Endocrinol 1994; 41: 615–20

    Article  CAS  Google Scholar 

  46. Johansson JO, Landin K, Johannsson G, et al. Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults. Thromb Haemost 1996; 76: 422–8

    PubMed  CAS  Google Scholar 

  47. Salomon F, Cuneo RC, Hesp R, et al. The effect of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 1989; 321: 1797–803

    Article  PubMed  CAS  Google Scholar 

  48. Russell-Jones DL, Watts GF, Weissberger AJ, et al. The effect of growth hormone replacement on serum lipids, lipoproteins, apolipoproteins and cholesterol precursors in adult growth hormone deficiency patients. Clin Endocrinol 1994; 41: 345–50

    Article  CAS  Google Scholar 

  49. Garry P, Collins P, Devlin JG. An open 36-month study of lipid changes with growth hormone in adults: lipid changes following replacement of growth hormone in adult acquired growth hormone deficiency. Eur J Endocrinol 1996; 134: 61–6

    Article  PubMed  CAS  Google Scholar 

  50. Berg K, Dahlen G, Frick MH. LP(a) lipoprotein and pre-beta1-lipoprotein in patients with coronary heart disease. Clin Genet 1974; 6: 230–5

    Article  PubMed  CAS  Google Scholar 

  51. Edén S, Wiklund O, Oscarsson J, et al. Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations. Arterioscler Thromb 1993; 13: 296–301

    Article  PubMed  Google Scholar 

  52. Burman P, Johansson AG, Siegbahn A et al. Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women. J Clin Endocrinol Metab 1997; 82: 550–5

    Article  PubMed  CAS  Google Scholar 

  53. Whitehead HM, Boreham C, Mcllrath EM, et al. Growth hormone treatment of adults with growth hormone deficiency: results of a 13-month placebo controlled cross-over study. Clin Endocrinol 1992; 36: 45–2

    Article  CAS  Google Scholar 

  54. Bengtsson BÅ, Edén S, Lonn L et al. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrin Metab 1993; 76: 309–17

    Article  CAS  Google Scholar 

  55. Jørgensen JOL, Vahl N, Hansen TB, et al. Growth hormone versus placebo treatment for one year in growth hormone deficient adults: increase in exercise capacity and normalization of body composition. Clin Endocrinol 1996; 45: 681–8

    Article  Google Scholar 

  56. Russell-Jones DL, Weissberger AJ, Bowes SB, et al. Protein metabolism in growth hormone deficiency, and effects of growth hormone replacement therapy. Acta Endocrinol 1993; 128Suppl. 2: 44–7

    PubMed  Google Scholar 

  57. Russell-Jones DL, Weissberger AJ, Bowes SB, et al. The effects of growth hormone on protein metabolism in adult growth hormone deficient patients. Clin Endocrinol 1993; 38: 427–31

    Article  CAS  Google Scholar 

  58. Nass R, Huber RM, Klauss V, et al. Effect of growth hormone (hGH) replacement therapy on physical work capacity and cardiac and pulmonary function in patients with hGH deficiency aquired in adulthood. J Clin Endocrinol Metab 1995; 80: 552–7

    Article  PubMed  CAS  Google Scholar 

  59. Jørgensen JOL, Pedersen SA, Thuesen L, et al. Long-term growth hormone treatment in growth hormone deficient adults. Acta Endocrinol 1991; 125: 449–53

    PubMed  Google Scholar 

  60. Jørgensen JOL, Thuesen L, Müller J, et al. Three years of growth hormone treatment in growth hormone-deficient adults: near normalization of body composition and physical performance. Eur J Endocrinol 1994; 130: 224–8

    Article  PubMed  Google Scholar 

  61. Beshyah SA, Shahi M, Skinner E, et al. Cardiovascular effects of growth hormone replacement therapy in hypopituitary adults. Eur J Endocrinol 1994; 130: 451–8

    Article  PubMed  CAS  Google Scholar 

  62. Johannsson G, Grimby G, Sunnerhagen KS, et al. Two years of growth hormone (GH) treatment increase isometric and isokinetic muscle strength in GH-deficient adults. J Clin Endocrinol Metab 1997; 82: 2877–84

    Article  PubMed  CAS  Google Scholar 

  63. Juul A, Behrenscheer A, Tims T, et al. Impaired thermoregulation in adults with growth hormone deficiency during heat exposure and exercise. Clin Endocrinol 1993; 38: 237–44

    Article  CAS  Google Scholar 

  64. Juul A, Hjortskov N, Jepsen LT, et al. Growth hormone deficiency and hyperthermia during exercise: a controlled study of sixteen GH-deficient patients. J Clin Endocrinol Metab 1995; 80: 3335–40

    Article  PubMed  CAS  Google Scholar 

  65. Pedersen SA, Welling K, Michaelsen KF, et al. Reduced sweating in adults with GH deficiency. Lancet 1989; II: 681–2

    Article  Google Scholar 

  66. Juul A, Main K, Nielsen B, et al. Decreased sweating in growth hormone deficiency: does it play a role in thermoregulation? J Pediatr Endocrinol 1993; 6: 39–44

    Article  PubMed  CAS  Google Scholar 

  67. Salomon F, Cuneo RC, Hesp R, et al. Basal metabolic rate in adults with growth hormone deficiency and in patients with acromegaly: relationship with lean body mass, plasma insulin level and leukocyte sodium pump activity. Clin sci 1992; 83: 325–30

    PubMed  CAS  Google Scholar 

  68. Stenlof K, Sjostrom L, Lonn L, et al. Effects of recombinant human growth hormone on basal metabolic rate in adults with pituitary deficiency. Metabolism 1995; 44: 67–74

    Article  PubMed  CAS  Google Scholar 

  69. Jørgensen JOL, Møller J, Skakkebaek NE, et al. Thyroid function during growth hormone therapy. Horm Res 1992; 38Suppl. 1: 63–7

    PubMed  Google Scholar 

  70. Møller J, Jørgensen JO, Müller N, et al. Effects of growth hormone administration on fuel oxidation and thyroid function in normal man. Metabolism 1992; 41: 728–31

    Article  PubMed  Google Scholar 

  71. Thorén M, Soop M, Degerblad M, et al. Preliminary study of the effects of growth hormone substitution therapy on bone mineral density and serum osteocalcin levels in adults with growth hormone deficiency. Acta Endocrinol 1993; 128:41–3

    PubMed  Google Scholar 

  72. Beshyah SA, Thomas E, Kyd P, et al. The effect of growth hormone replacement therapy in hypopituitary adults on calcium and bone metabolism. Clin Endocrinol 1994; 40:383–91

    Article  CAS  Google Scholar 

  73. Johansen JS, Pedersen SA, Jørgensen JOL, et al. Effects of growth hormone (GH) on plasma bone Gla-protein in GH-deficient adults. J Clin Endocrinol Metab 1990; 70: 916–9

    Article  PubMed  CAS  Google Scholar 

  74. Vandeweghe M, Taelman P, Kaufman JM. Short and long-term effects of growth hormone treatment on bone turnover and bone mineral content in adult growth hormone-deficient males. Clin Endocrinol 1993; 39: 409–15

    Article  CAS  Google Scholar 

  75. Schlemmer A, Johansen JS, Pedersen SA, et al. The effect of growth hormone (GH) therapy on urinary pyridinoline crosslinks in GH-deficient adults. Clin Endocrinol 1991; 35:471–6

    Article  CAS  Google Scholar 

  76. Van der Veen EA, Netelenbos JC. Growth hormone (replacement) therapy in adults: bone and calcium metabolism. Horm Res 1990; 33Suppl. 4: 65–8

    Article  PubMed  Google Scholar 

  77. Degerblad M, Elgindy N, Hall K, et al. Potent effect of recombinant growth hormone on bone mineral density and body composition in adults with panhypopituitarism. Acta Endocrinol 1992; 126: 387–93

    PubMed  CAS  Google Scholar 

  78. O’Halloran DJ, Tsatsoulis A, Whitehouse RW, et al. Increased bone density after recombinant human growth hormone (GH) therapy in adults with isolated GH deficiency. J Clin Endocrinol Metab 1993; 76: 1344–8

    Article  PubMed  Google Scholar 

  79. Balducci R, Toscano V, Pasquino AM, et al. Bone turnover and bone mineral density in young adult patients with panhypopituitarism before and after long-term growth hormone therapy. Eur J Endocrinol 1995; 132: 42–6

    Article  PubMed  CAS  Google Scholar 

  80. Holmes SJ, Shalet SM. Adult growth hormone deficiency and bone mass. Horm Res 1996; 45Suppl. 1: 69–71

    Article  PubMed  CAS  Google Scholar 

  81. Holmes SJ, Whitehouse RW, Swindell R, et al. Effect of growth hormone replacement on bone mass in adults with adult onset growth hormone deficiency. Clin Endocrinol 1995; 42: 627–33

    Article  CAS  Google Scholar 

  82. Baum HB, Biller BM, Finkelstein JS, et al. Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency: a randomized, placebo-controlled trial. Ann Intern Med 1996; 125: 883–90

    PubMed  CAS  Google Scholar 

  83. Johannsson G, Rosén T, Bosaeus I, et al. Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency. J Clin Endocrinol Metab 1996; 81: 2865–73

    Article  PubMed  CAS  Google Scholar 

  84. Binnerts A, Swart GR, Wilson JHP, et al. The effect of growth hormone administration in growth hormone deficient adults on bone, protein, carbohydrate and lipid homeostasis, as well as on body composition. Clin Endocrinol 1992; 37: 79–87

    Article  CAS  Google Scholar 

  85. McGauley GA. Quality of life assessment before and after growth hormone treatment in adults with growth hormone deficiency. Acta Paediatr Scand Suppl. 1989; 356: 70–2

    Article  PubMed  CAS  Google Scholar 

  86. McGauley GA, Cuneo RC, Salomon F, et al. Psychological well-being before and after growth hormone treatment in adults with growth hormone deficiency. Horm Res 1990; 33: 52–4

    Article  PubMed  Google Scholar 

  87. Burman P, Broman JE, Hetta J, et al. Quality of life in adults with growth hormone deficiency: response to treatment with recombinant human GH in a placebo-controlled 21-month trial. J Clin Endocrinol Metab 1995; 80: 3585–90

    Article  PubMed  CAS  Google Scholar 

  88. Almquist O, Thoren M, Saaf M, et al. Effects of growth hormone substitution on mental performance in adults with growth hormone deficiency: a pilot study. Psychoneuroendo-crinology 1986; 11(3): 347–52

    Article  Google Scholar 

  89. Nyberg F, Burman P. Growth hormone and its receptors in the central nervous system: location and functional significance. Horm Res 1996; 45: 18–22

    Article  PubMed  CAS  Google Scholar 

  90. Johansson JO, Larson G, Andersson M, et al. Treatment of growth hormone-deficient adults with recombinant human growth hormone increases the concentration of growth hormone in the cerebrospinal fluid and affects neurotransmitters. Neuroendocrinology 1995; 61: 57–66

    Article  PubMed  CAS  Google Scholar 

  91. Burman P, Hetta J, Wide L, et al. Growth hormone treatment affects brain neurotransmitters and thyroxine. Clin Endocrinol 1996; 44: 319–24

    Article  CAS  Google Scholar 

  92. Mendelson WB, Slater S, Gold P, et al. The effect of growth hormone administration on human sleep: a dose-response study. Biol Psychiatry 1980; 15(4): 613–6

    PubMed  CAS  Google Scholar 

  93. Åstrøm C, Christensen L, Gjerris F, et al. Sleep in acromegaly before and after treatment with adenectomy. Neuroendocrinology 1992; 53: 328–31

    Google Scholar 

  94. Astrom C, Lindholm J. Growth hormone-deficient young adults have decreased deep sleep. Neuroendocrinology 1990; 51: 82–4

    Article  PubMed  CAS  Google Scholar 

  95. Åstrøm C, Pedersen SA, Lindholm J. The influence of growth hormone on sleep in adults with growth hormone deficiency. Clin Endocrinol 1990; 33: 495–500

    Article  Google Scholar 

  96. Møller J, Jørgensen JOL, Møller N, et al. Expansion of extracellular volume and suppression of atrial natriuretic peptide after growth hormone administration in normal man. J Clin Endocrinol Metab 1991; 72: 768–72

    Article  PubMed  Google Scholar 

  97. Hoffman DM, Crampton L, Sernia C, et al. Short-term growth-hormone (GH) treatment of GH-deficient adults increases body sodium and extracellular water, but not blood pressure. J Clin Endocrinol Metab 1996; 81: 1123–8

    Article  PubMed  CAS  Google Scholar 

  98. Ho KY, Weissbuger AJ. The antinatriuretic action of biosynthetic human growth hormone in man involves activation of the renin-angiotensin-aldosterone system. Metabolism 1990; 39: 133–7

    Article  PubMed  CAS  Google Scholar 

  99. Møller J, Møller N, Frandsen E, et al. Blockade of the reninangiotensin-aldosterone system prevents growth hormone-induced fluid retention in humans. Am J Physiol 1997; 272 (5 Pt 1): E803–8

    PubMed  Google Scholar 

  100. Mårdh G, Lundin K, Borg G, et al. Growth hormone replacement therapy in adult hypopituitary patients with growth hormone deficiency: combined data from 12 European placebo-controlled clinical trials. Endocrinol Metab 1994; 1: 43–50

    Google Scholar 

  101. de Boer H, Blok GJ, Popp-Snijders C, et al. Monitoring of growth hormone replacement therapy in adults, based on measurement of serum markers. J Clin Endocrinol Metab 1996; 81: 1371–7

    Article  PubMed  Google Scholar 

  102. Laursen T, Jørgensen JOL, Christiansen JS. Metabolic effects of growth hormone administered subcutaneously once or twice daily to growth hormone deficient adults. Clin Endocrinol 1994; 41: 337–43

    Article  CAS  Google Scholar 

  103. Jørgensen JOL, Møller N, Lauritzen T, et al. Evening versus morning injections of growth hormone (GH) in GH-deficient patients: effects on 24-hour patterns of circulating hormones and metabolites. J Clin Endocrinol Metab 1990; 70: 207–14

    Article  PubMed  Google Scholar 

  104. Jørgensen JOL, Møller J, Møller N, et al. Pharmacological aspects of growth hormone replacement therapy: route, frequency and timing of administration. Horm Res 1990; 33Suppl. 4: 77–82

    PubMed  Google Scholar 

  105. Jørgensen JT, Mortensen HB, Jørgensen JOL. Patient acceptance of Nordiject: a new drug delivery system for growth hormone. DICP-Ann Pharmacother 1991; 25: 585–8

    Google Scholar 

  106. Sönksen PH, Cuneo RC, Salomon F, et al. Growth hormone therapy in adults with growth hormone deficiency. Acta Paediatr Scand Suppl. 1991; 379: 139–46

    Article  PubMed  Google Scholar 

  107. Møller J, Lauersen T, Mindeholm L, et al. Serum growth hormone (GH) profiles after nasally administered GH in normal subjects and GH deficient patients. Clin Endocrinol 1994; 40: 511–3

    Article  Google Scholar 

  108. Ho KY, Weissberger AJ, Stuart MC, et al. The pharmacokinetics, safety and endocrine effects of authentic biosynthetic human growth hormone in normal subjects. Clin Endocrinol 1989; 30: 335–45

    Article  CAS  Google Scholar 

  109. de Boer H, Blok GJ, Voerman B, et al. The optimal growth hormone replacement dose in adults, derived from bioimpedance analysis. J Clin Endocrinol Metab 1995; 80: 2069–76

    Article  PubMed  Google Scholar 

  110. Watanabe S, Tsunematsu Y, Fujimoto J, et al. Leukemia in patients treated with growth hormone. Lancet 1988; I: 1159

    Article  Google Scholar 

  111. Stahnke N. Leukemia in growth-hormone treated patients: an update. Horm Res 1992; 38Suppl. 1: 56–62

    Article  PubMed  Google Scholar 

  112. Hintz RL. Untoward effects in patients treated with growth hormone in the USA. Horm Res 1992; 38Suppl. 1: 44–8

    Article  PubMed  Google Scholar 

  113. Blethen SL, Allen DB, Graves D, et al. Safety of recombinant deoxyribonucleic acid-derived growth hormone: the National Cooperative Growth Study experience. J Clin Endocrinol Metab 1996; 81: 1704–10

    Article  PubMed  CAS  Google Scholar 

  114. Moshang Jr T, Rundle AC, Graves DA, et al. Brain tumor recurrence in children treated with growth hormone: the National Cooperative Growth Study experience. J Pediatr 1996; 128 (5 Pt 2): S4–7

    Article  PubMed  Google Scholar 

  115. Arslanian SA, Becker DJ, Lee PA, et al. Growth hormone therapy and tumor recurrence: findings in children with brain neoplasms and hypopituitarism. Am J Dis Child 1985; 139: 347–50

    PubMed  CAS  Google Scholar 

  116. Cowell CT, Dietsch S. Adverse events during growth hormone therapy. J Pediatr Endocrinol Metab 1995; 8: 243–52

    Article  PubMed  CAS  Google Scholar 

  117. Davidson MB. Effect of growth hormone on carbohydrate and lipid metabolism. Endocr Rev 1987; 8: 115–31

    Article  PubMed  CAS  Google Scholar 

  118. Merimee TJ, Felig P, Marliss E, et al. Glucose and lipid homeostasis in the absence of human growth hormone. J Clin Invest 1971; 50: 579–82

    Article  Google Scholar 

  119. Johansson JO, Fowelin J, Landin K, et al. Growth hormone-deficient adults are insulin-resistant. Metabolism 1995; 44: 1126–9

    Article  PubMed  CAS  Google Scholar 

  120. Weaver JU, Monson JP, Noonan K, et al. The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypopituitary adults. J Clin Endocrinol Metab 1995; 80: 153–9

    Article  PubMed  CAS  Google Scholar 

  121. Fowelin J, Attvall S, Lager I, et al. Effects of treatment with recombinant human growth hormone on insulin sensitivity and glucose metabolism in adults with growth hormone deficiency. Metabolism 1993; 42: 1443–7

    Article  PubMed  CAS  Google Scholar 

  122. Lundin K, Berger L, Blomberg F, et al. Development of anti-hGH antibodies during therapy with authentic human growth hormone. Acta Paediatr Scand Suppl. 1991; 372: 167–8

    Article  PubMed  CAS  Google Scholar 

  123. Weaver JU, Thaventhiran L, Noonan K, et al. The effect of growth hormone replacement on Cortisol metabolism and glucocorticoid sensitivity in hypopituitary adults. Clin Endocrinol 1994; 41: 639–48

    Article  CAS  Google Scholar 

  124. Rodriguez-Arnao J, Perry L, Besser GM, et al. Growth hormone treatment in hypopituitary GH deficient adults reduces circulating cortisol levels during hydrocortisone replacement therapy. Clin Endocrinol 1996; 45: 33–7

    Article  CAS  Google Scholar 

  125. Attanasio AF, Lamberts SW, Matranga AM, et al. Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. J Clin Endocrinol Metab 1997; 82; 82–8

    Article  PubMed  CAS  Google Scholar 

  126. Deijen JB, de Boer H, Blok GJ, et al. Cognitive impairments and mood disturbances in growth hormone deficient men. Psychoneuroendocrinology 1996; 21: 313–22

    Article  PubMed  CAS  Google Scholar 

  127. Rudman D, Feller AG, Nagraj HS, et al. Effects of human growth hormone in men over 60 years old. N Engl J Med 1990; 323: 1–6

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Endocrinology, Veterans Affairs Medical Center, Washington, DC, USA

    Torstein R. Meling

  2. Department of Medicine, Division of Endocrinology, George Washington University, Washington, DC, USA

    Torstein R. Meling

Authors
  1. Torstein R. Meling
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Meling, T.R. Growth Hormone Deficiency in Adults. BioDrugs 9, 351–362 (1998). https://doi.org/10.2165/00063030-199809050-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-199809050-00001

Keywords

Search

Navigation